Wegovy Oral Tablet Approved in Great Britain, Marking First European Approval
Great Britain has become the first European market to approve the oral formulation of Wegovy (semaglutide), representing a significant advancement in long-term weight management. The Medicines and Healthcare products Regulatory Agency (MHRA) decision signifies the launch of the tablet version of the drug, transitioning from its previous daily injection format. This approval represents a key development within the third-generation GLP-1 therapies.
Wegovy is now available for individuals with a Body Mass Index (BMI) of 30 or higher, or those with co-existing medical conditions including high blood pressure, type 2 diabetes, or cardiovascular risk factors. Clinical trials demonstrated the efficacy of Wegovy tablets, alongside a structured diet and exercise plan, resulting in a substantial weight reduction of 13.61% compared to the placebo group. Participants required consistent adherence to the prescribed regimen for optimal results.
The MHRA’s approval underscores the potential of this new delivery method and positions Wegovy as a readily accessible option for patients seeking long-term weight management solutions.
Topics: #first #tablet #approved
